CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 73 enrolled
Drug / intervention
AIN457 +1 moredrug
Likely dose
AIN457 10 mg/Kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01051817
NCT01051817Phase 2Completed
CompareCT.gov

A Randomized, Multi-center, Double-blind, Proof-of-concept Study to Assess the Effect of Multiple Infusion of AIN457 (10 mg/kg) Versus Placebo on Disease Activity as Measured by MRI Scans Over a 24 Week Period in Patients With Relapsing-remitting Multiple Sclerosis

Novartis Pharmaceuticals·interventional·Posted Jan 20, 2010·Updated Feb 27, 2015

In Brief

A Phase 2 clinical trial evaluating AIN457 and Placebo for Relapsing-remitting Multiple Sclerosis and RRMS. Completed, enrolled 73 participants across 16 sites in 3 countries.

Detailed Summary

A randomized, multi-center, double-blind, proof-of-concept study to assess the effect of multiple infusions of AIN457 (10 mg/kg) versus placebo on disease activity as measured by MRI scans over a 24 week period in patients with relapsing-remitting multiple sclerosis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsing-remitting Multiple Sclerosis, RRMS
CountriesCzechia, Russia, Ukraine
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 20, 2010
Enrollment StartDec 1, 2009
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.4 years ago

Interventions

AIN457drug

infusion 10 mg/Kg

Placebodrug

infusion